GLP Toxicology Studies in Neuroscience
Toxicology is a defining step between exploratory research and clinical development. As programs move toward IND-enabling requirements, the need for...
preclinical drug development
Critical Endpoints in Preclinical Pain Studies: Behavioral, Biomarker, and Electrophysiology Assessments
Developing effective therapeutics for pain requires selecting endpoints that accurately reflect the biological, functional, and neurophysiological...
MD Biosciences Signs the Marseille Declaration
MD Biosciences has signed the Marseille Declaration, the first joint pharmaceutical industry statement on animal housing and use. By signing, we...
How Close Are We to Clinical Translation? Large-Animal Models for SCI
Spinal cord injury (SCI) remains one of the most challenging neurological conditions to treat, with few therapies successfully translating from the...
Approaches to Designing Preclinical Studies That Reflect Clinical Reality
Bridging the gap between preclinical and clinical research remains one of the most pressing challenges in drug development. While early-stage studies...
EWMA 2025: Groundbreaking AI-Driven Advancements in Wound Healing Models
MD Biosciences presented at the European Wound Management Association 2025 in Barcelona. Dr. Avital Schauder showcased groundbreaking research on...
Behavioral Assessments in Preclinical Models
Neurological diseases often result in a combination of motor and cognitive deficits. To gain a broader understanding of the underlying biological...
Importance of Diversity in Preclinical Stroke Models
The Need for Diversity in Animal Models The clinical population is diverse, including both sexes, older individuals, and those with comorbid...
Why are potential pain therapies getting lost in translation?
It is estimated that 1.5 billion people worldwide suffer from Chronic pain. While research has seen tremendous advances in our understanding of pain...